

Bidil[®] (isosorbide dinitrate/hydralazine) – First-time generic

- On April 12, 2022, Ingenus launched RiconPharma's [AB-rated](#) generic version of Arbor Pharmaceuticals' [Bidil \(isosorbide dinitrate/hydralazine\)](#) tablets.
 - In addition, Wilshire Pharmaceuticals launched an authorized brand alternative of Bidil on April 14, 2022.
- Bidil is approved for the treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to prolong time to hospitalization for heart failure, and to improve patient-reported functional status.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.